Antihypertensive Medication Patterns in Patients with Hypertension that is Harder to Control: Insights from the EnligHTN Study

INTRODUCTION: Many patients with hypertension have hypertension that is harder to control (defined as needing ≥ 2 antihypertensive medications) and fail to achieve adequate blood pressure (BP) control. We assessed treatment patterns and BP outcomes in a large, multinational cohort of patients initiating a third antihypertensive class whilst remaining on a stable regimen of two antihypertensives from different classes. METHODS: EnligHTN is an observational, longitudinal cohort study on hypertension management and outcomes. Data from the USA, UK, Germany, Spain, and Israel from 2018 to 2023, and Denmark from 2018 to 2024, were extracted from de-identified electronic medical records, claims data, and health registry sources. Adult patients with diagnosed hypertension were included if they initiated a third antihypertensive (index date) whilst remaining on a stable two-drug regimen. Baseline demographics and clinical characteristics, treatment patterns from index to 24 months, and BP control at 12 and 24 months from index were described. RESULTS: Data from 64,501 patients were included. Across countries and common third antihypertensive classes, the proportion of patients who discontinued their third medication after index ranged from 54% to 100% at 12 months and from 67% to 100% at 24 months. Among a subcohort of patients with BP measurements at 12 months from index, BP was below target in 23-89%. CONCLUSIONS: Many patients with harder-to-control hypertension discontinued their third class of antihypertensive within 1 year, and numerous did not achieve adequate BP control. These findings highlight a significant gap in current hypertension management and underscore the need for adherence-focused treatment strategies to improve treatment persistence and BP outcomes in these patients.

Authors

Institutions

Publication Details

Journal
Advances in Therapy
Published
2026-09-11
DOI
https://doi.org/10.1007/s12325-026-03771-5
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antihypertensive Medication Patterns in Patients with Hypertension that is Harder to Control: Insights from the EnligHTN Study

Joachim Weil, Kirsty Rhodes, Vivek Bhalla, Clement Erhard et al.
Advances in Therapy
Blood Pressure and Hypertension Studies
article

Antihypertensive Medication Patterns in Patients with Hypertension that is Harder to Control: Insights from the EnligHTN Study

Joachim Weil, Kirsty Rhodes, Vivek Bhalla, Clement Erhard, Søren H. Christiansen, Esteban Coto, Tom Norris, Naomi R. Ben Dor, Terry McCormack, Jesper N. Bech, Julian Segura, Ina T. Andersen
article en

Abstract

INTRODUCTION: Many patients with hypertension have hypertension that is harder to control (defined as needing ≥ 2 antihypertensive medications) and fail to achieve adequate blood pressure (BP) control. We assessed treatment patterns and BP outcomes in a large, multinational cohort of patients initiating a third antihypertensive class whilst remaining on a stable regimen of two antihypertensives from different classes. METHODS: EnligHTN is an observational, longitudinal cohort study on hypertension management and outcomes. Data from the USA, UK, Germany, Spain, and Israel from 2018 to 2023, and Denmark from 2018 to 2024, were extracted from de-identified electronic medical records, claims data, and health registry sources. Adult patients with diagnosed hypertension were included if they initiated a third antihypertensive (index date) whilst remaining on a stable two-drug regimen. Baseline demographics and clinical characteristics, treatment patterns from index to 24 months, and BP control at 12 and 24 months from index were described. RESULTS: Data from 64,501 patients were included. Across countries and common third antihypertensive classes, the proportion of patients who discontinued their third medication after index ranged from 54% to 100% at 12 months and from 67% to 100% at 24 months. Among a subcohort of patients with BP measurements at 12 months from index, BP was below target in 23-89%. CONCLUSIONS: Many patients with harder-to-control hypertension discontinued their third class of antihypertensive within 1 year, and numerous did not achieve adequate BP control. These findings highlight a significant gap in current hypertension management and underscore the need for adherence-focused treatment strategies to improve treatment persistence and BP outcomes in these patients.

Advances in Therapy
Tel Aviv University (IL), Rabin Medical Center (IL), Aarhus University Hospital (DK), Hospital Universitario 12 De Octubre (ES), AstraZeneca (France) (FR), AstraZeneca (Switzerland) (CH), AstraZeneca (Japan) (JP), AstraZeneca (Poland) (PL), AstraZeneca (Finland) (FI), AstraZeneca (Italy) (IT), Clalit Health Services (IL), Hull York Medical School (GB), Stanford University (US)
AstraZeneca, Aarhus Universitet
Good health and well-being
Openalex Percentile: Top 11%
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.